Switch to:
Also traded in: Germany
» Details

Insider Trades

Latest Guru Trades with AFFY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:HDVY, OTCPK:MDFZF, OTCPK:BTHE, OTCPK:GOVX, OTCPK:ICOTF, OTCPK:TIKRF, OTCPK:CAPS, OTCPK:LCAR, OTCPK:BPSR, OTCPK:CTTC, OTCPK:VXLLF, OTCPK:ISCO, OTCPK:CBBT, OTCPK:ENTB, OTCPK:FPMI, OTCPK:ENDV, OTCPK:TLOG, OTCPK:PTEO, OTCPK:ERGO, OTCPK:NTRR » details
Traded in other countries:A5Y.Germany,
Affymax Inc is a biopharmaceutical company in the process of restructuring operations.

Affymax Inc was incorporated in Delaware in July 2001. The Company is a biopharmaceutical company in the process of restructuring operations. In March 2012, the U.S. Food and Drug Administration, or FDA, approved the Company's first and only product, OMONTYS or peginesatide Injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S. In March 2013, Company implemented plans to restructure its operations in order to reduce operating costs and focus on the OMONTYS safety and other related FDA issues associated with the recall of the product. Until the product recall in February 2013, final OMONTYS drug product was manufactured as a buffered aqueous solution for intravenous or subcutaneous administration. Under its collaboration with Takeda, Company was responsible, through its contract manufacturing organizations, or CMOs, for the manufacture and supply of all quantities of OMONTYS active pharmaceutical ingredient, or API, to be used in development and commercialization around the world, and Takeda was responsible for final drug product manufacture and control. In the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $0.04
EPS (TTM) $ 0.06
Beta2.37
Short Percentage of Float49.35%
52-Week Range $0.05 - 0.10
Shares Outstanding (Mil)37.49
» More Articles for AFFY

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: PII, ASNA, FIO, VVUS, AFFY Jul 23 2012 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 52,896 Shares May 19 2010 
AFFYMAX, INC. (AFFY) CEO Arlene Morris sells 180,410 Shares May 13 2010 
AFFYMAX, INC. (AFFY) EVP, Corp. Development and CFO Paul B Cleveland sells 55,935 Shares Feb 26 2010 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 101,100 Shares Sep 30 2009 
AFFYMAX, INC. (AFFY) President and CEO Arlene Morris sells 6,555 Shares Sep 02 2009 
AFFYMAX, INC. Reports Operating Results (10-Q) Aug 05 2009 

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK